Argus Research
- Home
- CHE
CHE
Chemed Corp
as of 03-06-2026 3:40pm EST
$408.64
$3.52
-0.85%
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
| Founded: | 1970 | Country: | United States |
| Employees: | 15695 | City: | CINCINNATI |
| Market Cap: | 5.6B | IPO Year: | 1994 |
| Target Price: | $498.00 | AVG Volume (30 days): | 225.1K |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | Dividend Payout Frequency: | quarterly | |
| EPS: | 18.34 | EPS Growth: | -7.79 |
| 52 Week Low/High: | $385.00 - $623.61 | Next Earning Date: | 06-02-2026 |
| Revenue: | $2,529,978,000 | Revenue Growth: | 4.06% |
| Revenue Growth (this year): | 6.6% | Revenue Growth (next year): | 6.15% |
| P/E Ratio: | 22.26 | Index: | N/A |
| Free Cash Flow: | 325.5M | FCF Growth: | -11.55% |
AI-Powered CHE Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 77.02%
77.02%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 25, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 25, 2026 · 100% conf.
AI Prediction BUY
1D
+4.46%
$487.40
5D
+6.63%
$497.53
20D
+7.99%
$503.87
Price: $466.60 Prob +5D: 100% AUC: 1.000
0000019584-26-000002
che-20260225x8k
false000001958400000195842026-02-252026-02-25
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): February 25, 2026
CHEMED CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 1-8351 31-0791746
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification Number)
2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202 (Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (513) 762-6690
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12) [_] Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b)) [_] Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))
Securities registered pursuant to 12(b) of the Act:
Title of each class
Trading symbol Name of each exchange on which registered
Capital stock $1 par value CHE
NYSE
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. [_]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]
Page 1 of 3
Item 2.02 Results of Operations and Financial Condition
On February 25, 2026, Chemed Corporation issued a press release announcing its financial results for the quarter ended December 31, 2025. A copy of the release is furnished herewith as Exhibit 99.
Item 9.01 Financial Statements and Exhibits
d) Exhibit
(99) Registrant’s press release dated December 31, 2025
104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL
Page 2 of 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CHEMED CORPORATION
Dated: February 25, 2026
By: /s/ Michael D. Witzeman
Michael D. Witzeman
Executive Vice President and Chief Financial Officer
Page 3 of 3
2025 Q3 Q3 2025 Earnings
8-K Oct 28, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 28, 2025
0000019584-25-000004
che-20251028x8k
false000001958400000195842025-10-282025-10-28
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): October 28, 2025
CHEMED CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 1-8351 31-0791746
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification Number)
2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202 (Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (513) 762-6690
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12) [_] Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b)) [_] Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))
Securities registered pursuant to 12(b) of the Act:
Title of each class
Trading symbol Name of each exchange on which registered
Capital stock $1 par value CHE
NYSE
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. [_]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]
Page 1 of 3
Item 2.02 Results of Operations and Financial Condition
On October 28, 2025, Chemed Corporation issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the release is furnished herewith as Exhibit 99.
Item 9.01 Financial Statements and Exhibits
d) Exhibit
(99) Registrant’s press release dated September 30, 2025
104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL
Page 2 of 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CHEMED CORPORATION
Dated: October 28, 2025
By: /s/ Michael D. Witzeman
Michael D. Witzeman
Executive Vice President and Chief Financial Officer
Page 3 of 3
2025 Q2 Q2 2025 Earnings
8-K Jul 29, 2025
2025
Q2
Q2 2025 Earnings
8-KJul 29, 2025
0001562762-25-000181
che-20250729x8k
false000001958400000195842025-07-292025-07-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): July 29, 2025
CHEMED CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 1-8351 31-0791746
(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification Number)
2600 First Financial Center, 255 East 5th Street, Cincinnati, OH 45202 (Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (513) 762-6690
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240-14a-12) [_] Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240-14d-2(b)) [_] Pre-commencement communications pursuant to Rule 13e-4 (c) under Exchange Act (17 CFR 240-13e-4(c))
Securities registered pursuant to 12(b) of the Act:
Title of each class
Trading symbol Name of each exchange on which registered
Capital stock $1 par value CHE
NYSE
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. [_]
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]
Page 1 of 3
Item 2.02 Results of Operations and Financial Condition
On July 29, 2025, Chemed Corporation issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the release is furnished herewith as Exhibit 99.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors: Appointment of Certain Officers, Compensatory Arrangements of Certain Officers.
(b) Nicholas M. Westfall, Executive Vice President of Chemed Corporation (the “Company”) and Chairman and Chief Executive Officer of Vitas, advised that he is resigning as Chairman and Chief Executive Officer of Vitas effective as of July 29, 2025, to pursue other interests. He will continue as Executive Vice President of Chemed and will assist with the transition of his duties until December 1, 2025. A copy of the press release announcing the events described above is attached hereto as Exhibit 99.
Item 9.01 Financial Statements and Exhibits
d) Exhibit
(99) Registrant’s press release dated June 30, 2025
104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL
Page 2 of 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CHEMED CORPORATION
Dated: July 29, 2025
By: /s/ Michael D. Witzeman
Michael D. Witzeman
Executive Vice President and Chief Financial Officer
Page 3 of 3
Latest Chemed Corp News
CHE Breaking Stock News: Dive into CHE Ticker-Specific Updates for Smart Investing
Compare CHE vs Leading Stocks
See how CHE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "CHE Chemed Corp - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.